💉 MMR Two-Dose Schedule Seroconversion Simulator

Pre-Vaccination — No Measles Antibodies Present

Every child starts with zero measles-specific antibody protection.

• 12–18: Measles R0 (most contagious known virus)
• 100%: Baseline susceptibility (before any dose)
• 6–12 mo: Maternal antibody wane (protection fades early)
• ~95%: Herd immunity threshold (coverage needed to block spread)

Why newborns start unprotected

Maternal antibodies cross the placenta before birth.

They fade within the first year of life.

A short immunity gap follows before vaccination.

Measles is extraordinarily contagious

One infected person can infect 12 to 18 others.

The virus lingers airborne in a room for hours.

Unvaccinated pockets ignite fast local outbreaks.

Measles needs about 95% population immunity to stop spreading.

Why two doses were adopted

A single dose alone leaves gaps in coverage.

Health agencies added a routine second dose.

The schedule now targets near-complete population protection.

First Dose At 12–15 Months — Initial Seroconversion

About 93% of children develop protective antibodies after dose one.

• ~93%: Dose-one seroconversion (live attenuated MMR)
• 12–15 mo: Recommended age (ACIP / WHO guidance)
• 2–3 wk: Antibody rise window (post-injection)
• ~93%: Single-dose efficacy (against measles disease)

Timing balances risk and response

Earlier doses meet lingering maternal antibody interference.

12 to 15 months maximizes reliable seroconversion.

Delaying further raises exposure risk needlessly.

How the live vaccine works

A weakened measles virus mimics natural infection.

The immune system builds memory B cells and antibodies.

Protection typically appears within two to three weeks.

Ninety-three percent is not enough alone

A 7% gap remains after just one dose.

That gap can still sustain local outbreaks.

A second dose was added to close it.

One dose protects most children but leaves real outbreak risk.

Primary Non-Responders — The Seven Percent Gap

Roughly 7% of children fail to seroconvert after their first dose.

• ~7%: Primary non-response rate (after dose one)
• Maternal Ab: Main cause (residual interference)
• None: Clinical symptoms (children appear healthy)
• Titer test: Detection method (only way to confirm)

Why some children do not respond

Leftover maternal antibodies can neutralize the vaccine strain.

Younger age at dosing raises this risk slightly.

Cold-chain handling issues can also reduce potency.

Non-responders are invisible without testing

These children look and act completely normal.

No symptom distinguishes them from protected peers.

Only serology reveals the missing antibody response.

Seven percent sounds small but scales into thousands per cohort.

This gap drives the two-dose policy

A second dose is not a simple booster.

For non-responders, it functions as a first true dose.

Most of this group finally seroconverts then.

Second Dose At 4–6 Years — Catching The Gap

The second dose captures most children who missed dose one.

• 4–6 yr: Recommended age (school-entry schedule)
• ~64%: Non-responders converting now (of the original 7%)
• ~2.5%: Remaining unprotected (after both doses)
• Higher: Titer boost in responders (reinforced antibody levels)

A true second chance to seroconvert

Most first-dose non-responders finally build antibodies now.

Maternal antibody interference is long gone by this age.

The immune system responds far more reliably.

Also reinforces existing protection

Children already protected get a titer boost too.

Higher, longer-lasting antibody levels result.

This adds durability across childhood and beyond.

A small residual gap remains

A tiny fraction still does not seroconvert.

This is true secondary vaccine failure.

High two-dose coverage still keeps communities safe.

School-entry requirements make dose two a population safety net.

Post-Second-Dose Protection — Over 97% Immune

Two doses push measles protection above 97% of the population.

• >97%: Two-dose measles efficacy (CDC / WHO estimate)
• ~88%: Two-dose mumps efficacy (MMR combined vaccine)
• ~97%: Two-dose rubella efficacy (MMR combined vaccine)
• Met: Elimination threshold (at high coverage levels)

From 93% to over 97%

One dose alone leaves meaningful outbreak risk.

Two doses close most of that remaining gap.

Population-level protection becomes durable and reliable.

Why this threshold matters for everyone

High two-dose coverage approaches herd immunity thresholds.

Infants too young for vaccination gain indirect protection.

Immunocompromised people also benefit from reduced circulation.

High coverage protects those who cannot be vaccinated themselves.

Coverage gaps still cause outbreaks

Local pockets of under-vaccination remain vulnerable.

Imported cases can spark clusters there quickly.

Sustained high coverage is the durable defense.